CSBR - CIK 0000771856
The table below shows CHAMPIONS ONCOLOGY, INC.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $7.39M | -$6.14M | $3.97M | $6.50M | -$1.68M | $2.90M |
| Capital expenditure | $389.00K | $836.00K | $2.87M | $2.38M | $3.28M | $2.22M |
| Investing cash flow | -$389.00K | -$836.00K | -$2.87M | -$2.38M | -$3.17M | -$2.22M |
| Dividends paid | - | - | - | - | - |
CHAMPIONS ONCOLOGY, INC. reported operating cash flow of $7.39M for fiscal year 2025. That is up 220.4% from -$6.14M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$6.41M (FY 2016) to $7.39M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | $0.00 | $634.00K | $74.00K | $0.00 | - | - |
| Financing cash flow | $170.00K | -$527.00K | $11.00K | $207.00K | $1.20M | $4.42M |